lyophilisation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Over the coming decade, Libya developed stronger political and economic links with Dom Mintoff's Maltese administration, and under Libya's urging Malta did not renew the UK's airbases in 1980. Orchestrating a military build-up, the RCC began purchasing weapons from France and the Soviet Union. The commercial relationship with the latter led to an increasingly strained relationship with the US, which was then engaged in the Cold War with the Soviets.
Among numerous advances in experimental techniques he has developed experimental methods for using DNA microarrays to investigate the basic principles of genome organization. Member Natl. Acad. Sci. USA. Thomas Bruice (1925–2019). American bioorganic chemist at UC Santa Barbara, pioneering researcher in chemical biology. Member Natl. Acad. Sci. USA.
=== Sample condition === The sample should be in good contact with the crucible surface. Therefore, the contact surface of a solid bulk sample should be plane parallel. For DSC measurements with powders, stronger signal might be observed for finer powders due to the enlarged contact surface. The minimum sample mass depends on the transformation to be analyzed. A small sample mass (~10 mg) is sufficient if the released or consumed heat during the transformation is high enough. Heavier samples could be used to obtain transformation associated with low heat release or consumption, as larger samples also enlarge the obtained peaks. However, the increasing sample size might worsen the resolution due to thermal gradients which may evolve during heating.
Sources: en.wikipedia.org
== Adverse reactions == Sleeping pills, including zopiclone, have been associated with an increased risk of death. The British National Formulary states adverse reactions as follows: "taste disturbance (some report a metallic taste); less commonly nausea, vomiting, dizziness, drowsiness, dry mouth, headache; rarely amnesia, confusion, depression, hallucinations, nightmares; very rarely light-headedness, incoordination, paradoxical effects [...] and sleep-walking also reported". Long-term use of Z-drugs, including zopiclone, has been associated with dependence, withdrawal symptoms, and cognitive impairment.
David Kogan , has worked as journalist and senior executive at the BBC, Reuters Television, Granada Channels, Wasserman Media Group and Magnum Photos; producer working on Today; at BBC Television working on Newsnight and Breakfast Time; and at BBC America; was managing editor - global managing director at Reuters Television; was executive director at Granada Channels and was executive director/CEO of Magnum Photos from 2015 to 2019.; was Premier League's chief media rights adviser.; was awarded OBE .; director of LabourList, an independent news site for the Labour Party. He resigned as director in April 2025. Daniel Korski (born April 1977); Polish Jewish ancestry, journalist, political adviser and businessperson; worked as deputy head of Number 10 Policy Unit for David Cameron; vice-president of Jewish Leadership Council. Korski reported for Financial Times, Jewish News, then The Spectator as war correspondent in Libya. In 2008, he was described as a "Balkans expert" working at the European Council on Foreign Relations (ECFR), a think tank. In 2011, he was working as a senior policy fellow for the ECFR and running the Middle East programme there. In 2012, was appointed as strategic adviser to Catherine Ashton, then working as High Representative of the Union for Foreign Affairs and Security Policy; was made a Commander of the Order of British Empire (CBE) in 2016 as part of David Cameron's resignation honours alongside other advisers.
=== Surgery === Aggressive wound debridement should be performed as soon as the diagnosis is made. The affected area may need to be debrided several times, usually once every 12–36 hours. Large sections of tissue and muscle may need to be removed to prevent the infection from spreading. Amputation may be needed if the infection is too severe. En bloc debridement (EBd) is most commonly employed in treating NSTIs. This involves cutting away the skin overlying all diseased areas at the cost of increased scar formation and potential decreased quality of life post-operatively. More recently, skin-sparing debridement (SSd) has gained traction, as it resects the underlying tissue and sources of infection while preserving skin that is not overtly necrotic. However, more studies are needed to examine whether SSd actually accelerates the healing process after surgery.
=== Christianised forms === Most of the Grail romances do not differ much from Perceval. The two pieces that hold particularly stronger Christian themes than prior works are the influential Vulgate and Post-Vulgate versions of the Queste del Saint Graal (featured in Malory's compilation) and the Sone de Nausay. The Queste del Saint Graal is heavily Christian not only in terms of the tone but also the characters and significant objects. The Grail maidens become angels, there is a constant relationship between the knights and religious symbolism; most importantly, the Fisher King is replicated as a priest-like figure. In the case of Sone de Nausay, Bron (the Fisher King) is part of a tale in which the story makes a constant correlation between the Gospel narrative and the history of the Grail.
Sources: en.wikipedia.org
=== Whole-mass determination === The protein’s whole mass is the sum of the masses of its amino-acid residues plus the mass of a water molecule and adjusted for any post-translational modifications. Although proteins ionize less well than the peptides derived from them, a protein in solution may be able to be subjected to ESI-MS and its mass measured to an accuracy of 1 part in 20,000 or better. This is often sufficient to confirm the termini (thus that the protein’s measured mass matches that predicted from its sequence) and infer the presence or absence of many post-translational modifications.
== G == G3P – gall – gall-inducing insect – gamete – gametophyte – gastrula – gel electrophoresis – gene – genetic drift – gene duplication – gene pool – genetic code – genetic equilibrium – genetic fingerprint – genetic recombination – genetics – gene regulatory network – genetic carrier – gene therapy – genome – genome project – genomics – genotype – geologic time – George W. Beadle – glucose – glycolipid – glycolysis – glycome – glycomics – glycoprotein – glycoprotein – Gobind Khorana – Golgi apparatus – Gondwana – gradient – gravitational biology – gravitropism – Gregor Mendel – ground tissue – growth curve – Guthrie test
== Boards of Directors == Bowman has served on the boards of directors of a number of companies in the areas of innovative technologies and the life sciences in addition to Dionex. From 1985 to 2007, Bowman served as a director of Molecular Devices Corporation, a supplier of bioanalytical measurement instruments. In 2006, he was appointed lead director of the board of Cell BioSciences, a privately held company engaged in protein research in the emerging area of nanoproteomics. He was appointed to the board of Solexa, Inc. in 2006. Solexa, which developed genome sequencing technology, was acquired in 2007 by Illumina, Inc., on whose board of directors Bowman now serves. Illumina develops tools for DNA, RNA, and protein analysis. A. Blaine Bowman joined Altera Corporation's board of directors as of July 30, 2012. Altera develops programmable logic devices.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.